SCHEMBL4753154

SCHEMBL4753154

CC(=O)OC1C[C@@]2(C)C(=CC1=O)CC[C@H]1[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)CC[C@@H]12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.67
CYP3A4 P08684 6/20 0.67
SMN1; SMN2 Q16637 6/20 0.67
LMNA P02545 4/20 0.67
MAPT P10636 4/20 0.67
MAPK1 P28482 3/20 0.67
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
SERPINA6 P08185 3/20 0.67
CYP2C9 P11712 2/20 0.67
TSHR P16473 2/20 0.67
HIF1A Q16665 2/20 0.67
ABCB11 O95342 2/20 0.67
SHBG P04278 2/20 0.67
NR3C2 P08235 2/20 0.67
CYP2C19 P33261 1/20 0.67
KDM4E B2RXH2 1/20 0.67
SLC22A2 O15244 1/20 0.67
SLC22A1 O15245 1/20 0.67
NR1I2 O75469 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11023741 0.90 CYP3A4 (0.62) ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT
SCHEMBL11021611 0.89 ALDH1A1 (0.61) ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT
SCHEMBL571657 0.89 CYP3A4 (0.61) ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT
SCHEMBL11414100 0.86 ALDH1A1 (0.65) ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT
SCHEMBL23748331 0.86 CYP3A4 (0.71) ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT
SCHEMBL4747201 0.86 CYP3A4 (0.71) ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT
SCHEMBL674222 0.86 CYP3A4 (0.71) ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT
SCHEMBL9640298 0.86 SMN1; SMN2 (0.71) ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT
SCHEMBL7992724 0.86 CYP3A4 (0.71) ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT
SCHEMBL29127389 0.85 CYP3A4 (0.69) ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106344233-B Casing for expansible medical device W.L.戈尔及同仁股份有限公司 2019-07-26 CN disclosed
EP-2613842-B1 INDWELLING LUMINAL DEVICES GORE & ASS (US) 2017-07-05 EP disclosed
US-9095601-B2 Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (“PNAs”) with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer WASHINGTON UNIVERSITY IN ST. LOUIS (US) 2015-08-04 US disclosed
US-20130230452-A1 CELL PERMEABLE NANOCONJUGATES OF SHELL-CROSSLINKED KNEDEL (SCK) AND PEPTIDE NUCLEIC ACIDS (\"PNAs\") WITH UNIQUELY EXPRESSED OR OVER-EXPRESSED mRNA TARGETING SEQUENCES FOR EARLY DIAGNOSIS AND THERAPY OF CANCER WASHINGTON UNIVERSITY (US) 2013-09-05 US disclosed
US-8354093-B2 Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (“PNAs”) with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer WASHINGTON UNIVERSITY (US) 2013-01-15 US disclosed
WO-2008148473-A2 METHOD FOR THE PRODUCTION OF 17 ALPHA-ACETOXY-6-METHYLENEPREGN-4-ENE-3,20-DIONE, MEDROXYPROGESTERONE ACETATE, AND MEGESTROL ACETATE BAYER SCHERING PHARMA AG (DE) 2008-12-11 WO disclosed
US-20070207204-A1 Dosage Form for Time-Varying Patterns of Drug Delivery ALZA CORPORATION (US) 2007-09-06 US disclosed
US-20060159619-A1 Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (\"PNAs\") with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-07-20 US disclosed
WO-2006044716-A2 CELL PERMEABLE NANOCONJUGATES OF SHELL-CROSSLINKED KNEDEL (SCK) AND PEPTIDE NUCLEIC ACIDS ('PNAs') WITH UNIQUELY EXPRESSED OR OVER-EXPRESSED mRNA TARGETING SEQUENCES FOR EARLY DIAGNOSIS AND THERAPY OF CANCER WASHINGTON UNIVERSITY IN ST.LOUIS (US) 2006-04-27 WO disclosed
EP-1492509-A1 DOSAGE FORM PROVIDING TIME-VARYING PATTERNS OF DRUG DELIVERY ALZA Corporation (US) 2005-01-05 EP disclosed
EP-0300623-A2 Dispenser with movable matrix comprising a plurality of tiny pills ALZA CORPORATION (US) 1989-01-25 EP disclosed
EP-0297725-A2 Dispenser with dispersing member for delivering beneficial agent ALZA CORPORATION (US) 1989-01-04 EP disclosed
US-4783337-A Osmotic system comprising plurality of members for dispensing drug ALZA CORPORATION (US) 1988-11-08 US disclosed
US-4772474-A Dispenser with internal arrangement of lamina means for dispensing beneficial agent ALZA CORPORATION (US) 1988-09-20 US disclosed
US-4729793-A Composition for manufacturing wall of dispensing device ALZA CORPORATION (US) 1988-03-08 US disclosed
US-4717718-A Device for the controlled delivery of a beneficial agent ALZA CORPORATION (US) 1988-01-05 US disclosed
US-4717568-A Laminar arrangement for increasing delivery of beneficial agent from dispenser ALZA CORPORATION (US) 1988-01-05 US disclosed
US-4692336-A Self controlled release device for administering beneficial agent to recipient ALZA CORPORATION (US) 1987-09-08 US disclosed
US-4624945-A Dispensing system with means for increasing delivery of beneficial agent from the system ALZA CORPORATION (US) 1986-11-25 US disclosed
EP-0054786-B1 6-ALPHA-METHYL HYDROCORTISONE DERIVATIVES, THEIR PREPARATION AND THEIR UTILIZATION SCHERING AKTIENGESELLSCHAFT (DE) 1985-03-20 EP disclosed